Sponsors / Partners

Accenture Microsoft NYSE Shell Salesforce AAAS Science Red Herring Fortune CNN Time Magazine
 

2004 World Technology Awards Winners & Finalists

Neurocrine Biosciences, Inc.

Please describe the work that you are doing that you consider to be the most innovative and of the greatest likely long-term significance.

Corporate Information:

Neurocrine Biosciences, Inc. is a product-based biopharmaceutical company focused on neurological and endocrine-related diseases and disorders. Our product candidates address some of the largest pharmaceutical markets in the world including insomnia, anxiety, depression, various female and male health disorders, multiple sclerosis, diabetes, irritable bowel syndrome, eating disorders, pain, and autoimmunity disorders.

Research:

Neurocrine's research organization is comprised of approximately 192 scientists in the departments of neuroscience, chemistry (including medicinal, analytical, peptide and computational), pharmacology, screening, and molecular biology. These scientists possess the skills and experience necessary to bring compounds from basic research concepts to drug candidate stage. Neurocrine utilizes advanced technologies to enhance its drug discovery capabilities and to accelerate the drug development process. Working together, Neurocrine's chemists, pharmacologists and biologists strive to create new solutions to unmet medical problems necessary to deliver a new drug candidate every 18 months.

Clinical Development:

Neurocrine currently has 17 programs in various stages of research and development. Seven of these programs have been advanced into clinical trials. Our lead clinical development program, indiplon , for the treatment of insomnia, partnered with Pfizer, is currently in Phase III trials with an NDA filing anticipated in the first half of 2004. We have successfully completed two Phase I trials with GnRH (Gonadotropin-releasing Hormone) for the treatment of women's health disorders. The Company has two Altered Peptide Ligand (APL) products in Phase II clinical development, NBI-5788 for multiple sclerosis, and NBI-6024 for Type I Diabetes. In July 2003 we initiated a Phase II trial for relapsing multiple sclerosis with results expected in 2005. Our diabetes program has successfully completed four Phase I/II trials with a Phase II dose response trial currently underway. Results from this trial are expected in late 2005. Neurocrine acquired the rights from Pharmaceia to develop indications related to male and female sexual dysfunction. We plan to initiate a Phase II proof of concept study early next year with NBI-69733 in the area of male erectile dysfunction to determine its potential efficacy. The Company's CRF program, partnered with GlaxoSmithKline is continuing to develop multiple compounds that are currently in various stages of research and preclinical development. Our IL-4 product candidate, NBI-3001 has completed a Phase I trial for solid tumor cancers and a Phase II trial for malignant glioma. We plan to outsource the development and commercialization of this compound allowing us to focus on neurological and endocrine-related diseases and disorders.